115 results on '"Campos, Verena Ramirez"'
Search Results
2. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
3. Efficacy and Safety of Fremanezumab in Patients with Migraine and Obesity: Post Hoc Analysis of the Phase 3 HALO-LTS and FOCUS Clinical Trials (P8-12.001)
4. Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study
5. Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: Results of the UNITE study
6. Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study
7. Immunogenicity of biologic therapies for migraine: a review of current evidence
8. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
9. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
10. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
11. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
12. No ‘Wearing-Off Effect’ Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use (P12-12.005)
13. Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
14. 086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes
15. 085 Medication overuse reversion following fremanezumab treatment in migraine patients with inadequate response to prior preventives
16. 056 Efficacy of fremanezumab in chronic migraine patients with inadequate response to ≥3 preventive medication classes
17. Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients With Migraine: A Pooled Analysis of Phase 3 Studies (P1-2.004)
18. Six-month Safety and Efficacy of Fremanezumab in Migraine: Pooled Analysis from the Phase 3 FOCUS and HALO Studies (S31.007)
19. Timing and Location of Injection-site Adverse Events With Fremanezumab in Patients With Migraine: A Pooled Analysis of Phase 3 Studies (P16-2.003)
20. Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis (P12-2.002)
21. Changes in Heart Rate and Blood Pressure in Participants Treated With Fremanezumab for Migraine: A Pooled Analysis of Phase 3 Studies (P3-2.003)
22. Efficacy and Disability Outcomes of Fremanezumab in Patients With Prior OnabotulinumtoxinA Treatment Failure: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies (P3-2.004)
23. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
24. sj-pdf-1-cep-10.1177_03331024221076485 - Supplemental material for Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
25. Pooled analysis of safety and efficacy of fremanezumab in different racial and ethnic subgroups of patients with migraine
26. Fremanezumab improves quality of life in patients with higher- and lower-frequency chronic migraine
27. Efficacy of fremanezumab in patients with chronic and episodic migraine stratified by migraine frequency
28. Efficacy and improvements in disability and quality-of-life with fremanezumab over 6 months in migraine patients with inadequate response by multiple prior preventive treatment classes
29. Reversion from medication overuse with fremanezumab treatment in patients with inadequate response to multiple migraine preventive medication classes
30. Progressive improvements in efficacy and disability with fremanezumab in patients with medication overuse and inadequate response to multiple migraine preventive medication classes
31. Fremanezumab improves quality of life in patients with high- and moderate-frequency episodic migraine
32. Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
33. Additional file 2 of Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
34. Additional file 3 of Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
35. sj-pdf-2-cep-10.1177_03331024211008401 - Supplemental material for Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
36. Additional file 5 of Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
37. Additional file 1 of Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
38. sj-pdf-1-cep-10.1177_03331024211008401 - Supplemental material for Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
39. Additional file 1 of Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
40. Additional file 4 of Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
41. Additional file 1 of Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
42. Fremanezumab for the Preventive Treatment of Migraine : Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
43. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine:results of the randomized, placebo-controlled, phase 3b FOCUS study
44. Efficacy of Fremanezumab in Patients With Moderate and Higher Frequency Episodic Migraine (4308)
45. Cardiovascular Safety of Fremanezumab in Patients With Migraine and Cardiovascular Medical History or Risk Factors: A Pooled Analysis of Phase 3 Studies (2382)
46. Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study (2124)
47. Efficacy of Fremanezumab in Patients With Lower and Higher Frequency Chronic Migraine (4300)
48. Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2–4 Prior Migraine Preventive Medication Classes (2055)
49. Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies (2254)
50. Efficacy and Safety of Fremanezumab in Patients with Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications during the Open Label Period of the Phase 3b FOCUS Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.